Business Description
Protara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74365U1079
Share Class Description:
TARA: Ordinary SharesDescription
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.5 | |||||
| 3-Year EPS without NRI Growth Rate | 8.8 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -30.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.3 | |||||
| 9-Day RSI | 43.57 | |||||
| 14-Day RSI | 41.68 | |||||
| 6-1 Month Momentum % | 184.1 | |||||
| 12-1 Month Momentum % | 14.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.17 | |||||
| Quick Ratio | 11.17 | |||||
| Cash Ratio | 10.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 2.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -47.29 | |||||
| ROA % | -41.91 | |||||
| ROIC % | -271.6 | |||||
| ROC (Joel Greenblatt) % | -570.1 | |||||
| ROCE % | -48.22 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.5 | |||||
| Price-to-Tangible-Book | 0.5 | |||||
| EV-to-EBIT | 0.58 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.58 | |||||
| EV-to-FCF | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.62 | |||||
| Earnings Yield (Greenblatt) % | 172.41 | |||||
| FCF Yield % | -109.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TARA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protara Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.57 | ||
| Beta | 1.94 | ||
| Volatility % | 105.83 | ||
| 14-Day RSI | 41.68 | ||
| 14-Day ATR ($) | 0.333585 | ||
| 20-Day SMA ($) | 3.4475 | ||
| 12-1 Month Momentum % | 14.53 | ||
| 52-Week Range ($) | 1.04 - 5.24 | ||
| Shares Outstanding (Mil) | 11.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protara Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Protara Therapeutics Inc Frequently Asked Questions
What is Protara Therapeutics Inc(TARA)'s stock price today?
The current price of TARA is $3.00. The 52 week high of TARA is $5.24 and 52 week low is $1.04.
When is next earnings date of Protara Therapeutics Inc(TARA)?
The next earnings date of Protara Therapeutics Inc(TARA) is 2024-05-03 Est..
Does Protara Therapeutics Inc(TARA) pay dividends? If so, how much?
Protara Therapeutics Inc(TARA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers